Statements (93)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:administered_by |
injection
|
| gptkbp:approves |
gptkb:1985
pediatric patients |
| gptkbp:atccode |
L02 AE01
|
| gptkbp:available_in |
multiple strengths
|
| gptkbp:brand |
gptkb:Lupron
gptkb:Lupron_Depot gptkb:Eligard |
| gptkbp:class |
gptkb:Hirogen
|
| gptkbp:clinical_trial |
Phase III
studies on safety in children studies on efficacy in children |
| gptkbp:condition |
uterine fibroids
hormone-sensitive cancers testosterone suppression ovarian suppression endometrial hyperplasia |
| gptkbp:contraindication |
pregnancy
breastfeeding hypersensitivity to leuprolide |
| gptkbp:dosage_form |
injectable solution
depot injection |
| gptkbp:duration |
varies by condition
variable based on condition |
| gptkbp:effective_date |
FDA approved
|
| gptkbp:financial_support |
avoid alcohol
report mood changes monitor bone density consult doctor before stopping treatment |
| gptkbp:form |
depot injection
|
| gptkbp:formulation |
long-acting
|
| gptkbp:frequency |
monthly
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lupron Depot
|
| gptkbp:indication |
gptkb:Oncology
gptkb:endometriosis uterine fibroids |
| gptkbp:ingredients |
gptkb:leuprolide_acetate
|
| gptkbp:interacts_with |
anticoagulants
may interact with anticoagulants hormonal contraceptives antidiabetic medications may interact with anticonvulsants may interact with other hormonal therapies |
| gptkbp:is_monitored_by |
growth rate
side effects bone density symptom relief hormone levels |
| gptkbp:manufacturer |
gptkb:Abb_Vie
|
| gptkbp:marketed_as |
gptkb:Lupron
|
| gptkbp:mechanism_of_action |
gptkb:Hirogen
|
| gptkbp:packaging |
vial
|
| gptkbp:patient_education |
potential side effects
importance of adherence need for regular follow-up |
| gptkbp:patient_population |
gptkb:children
adolescents adult men adult women children with precocious puberty |
| gptkbp:pharmacokinetics |
excreted in urine
subcutaneous absorption metabolized in liver |
| gptkbp:previous_name |
gptkb:leuprolide
|
| gptkbp:provides_guidance_on |
recommended for precocious puberty
used in gender dysphoria treatment used in hormone-sensitive cancers |
| gptkbp:regulatory_compliance |
FDA approved
EMA approved |
| gptkbp:route_of_administration |
injection
subcutaneous intramuscular |
| gptkbp:service_frequency |
monthly
|
| gptkbp:side_effect |
gptkb:anemia
gptkb:depression fatigue nausea weight gain headaches injection site reactions osteoporosis mood changes hot flashes decreased libido |
| gptkbp:storage |
room temperature
|
| gptkbp:structure |
C59 H84 N16 O12
|
| gptkbp:used_for |
gptkb:Oncology
gptkb:endometriosis precocious puberty treatment of precocious puberty |
| gptkbp:bfsParent |
gptkb:Lupron
|
| gptkbp:bfsLayer |
6
|